Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors

Epidermal growth factor receptor (EGFR) T790M mutation accounted for over half of drug resistance cases in EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) and led to different outcomes. This study aimed to assess the prognostic role of T790...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Guangzhi, Zhang, Jing, Jiang, Hai, Zhang, Nannan, Yin, Liyuan, Li, Wen, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725104/
https://www.ncbi.nlm.nih.gov/pubmed/29245913
http://dx.doi.org/10.18632/oncotarget.19681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725104/
https://www.ncbi.nlm.nih.gov/pubmed/29245913
http://dx.doi.org/10.18632/oncotarget.19681

Ejemplares similares